Follow-up of phase I trial of adalimumab and rosiglitazone in FSGS: III. Report of the FONT study group

Follow-up of phase I trial of adalimumab and rosiglitazone in FSGS: III. Report of the FONT study group is a paper indexed in ScholarIQ from OpenAlex.

How many citations does Follow-up of phase I trial of adalimumab and rosiglitazone in FSGS: III. Report of the FONT study group have?

Follow-up of phase I trial of adalimumab and rosiglitazone in FSGS: III. Report of the FONT study group has 39 citations in the OpenAlex counts ScholarIQ stores.

When was Follow-up of phase I trial of adalimumab and rosiglitazone in FSGS: III. Report of the FONT study group published?

Follow-up of phase I trial of adalimumab and rosiglitazone in FSGS: III. Report of the FONT study group has 2010 year in the ScholarIQ index.

What is the open-access status of Follow-up of phase I trial of adalimumab and rosiglitazone in FSGS: III. Report of the FONT study group?

Follow-up of phase I trial of adalimumab and rosiglitazone in FSGS: III. Report of the FONT study group has gold oa status in the ScholarIQ index.

What is the DOI of Follow-up of phase I trial of adalimumab and rosiglitazone in FSGS: III. Report of the FONT study group?

The DOI for Follow-up of phase I trial of adalimumab and rosiglitazone in FSGS: III. Report of the FONT study group is on the source record.

What is the PMID of Follow-up of phase I trial of adalimumab and rosiglitazone in FSGS: III. Report of the FONT study group?

The PMID for Follow-up of phase I trial of adalimumab and rosiglitazone in FSGS: III. Report of the FONT study group is on the source record.

What is the OpenAlex record for Follow-up of phase I trial of adalimumab and rosiglitazone in FSGS: III. Report of the FONT study group?

The OpenAlex for Follow-up of phase I trial of adalimumab and rosiglitazone in FSGS: III. Report of the FONT study group is on the source record.